Skip to content

Clinical trials

Autism Spectrum Disorder trials with no applicable phase and unknown status

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Autism Spectrum Disorder Phase: Not applicable Status: Unknown status Clear all

135 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20092
20103
20112
20122
20142
20153
20162
20176
20187
201917
202011
202113
202223
202330
202412

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Unknown status135

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Istituto per la Ricerca e l'Innovazione Biomedica11
Chang Gung Memorial Hospital5
All India Institute of Medical Sciences3
Bar-Ilan University, Israel3
Changping Laboratory3
Holland Bloorview Kids Rehabilitation Hospital3
National Taiwan University Hospital3
Assistance Publique - Hôpitaux de Paris2
King's College London2
Midlands Psychology CIC2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Autism Spectrum Disorder135
Autistic Disorder40
Anxiety Disorders6
Neurodevelopmental Disorders6
Asperger Syndrome4
Developmental Disabilities4
Brain Injuries, Traumatic3
Motor Skills Disorders3
Attention Deficit Disorder with Hyperactivity2
Feeding and Eating Disorders2

Trials

Showing 1 to 25 of 135. Each trial links to its page on Pharma Observatory.

35 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.